Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Major histocompatibility complex abnormalities in non-Hodgkin lymphomas.

Bernard Drénou1, Gaelle Le Friec, Marc Bernard

  • 1Laboratoire Universitaire d'Hématologie et de la Biologie des Cellules Sanguines, UPRES EA 22.33, Rennes, France. bernard-drenou@univ-rennes1.fr

British Journal of Haematology
|October 31, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sp1 links CD46 to CD4 T cell metabolic fitness, survival, and retroviral control.

Science immunology·2026
Same author

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same author

Diagnosis of NK-Large Granular Lymphocytic Leukemia.

Blood advances·2026
Same author

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same author

Central nervous system involvement in multiple myeloma as a first manifestation of relapse and potential diagnostic pitfall.

Cytometry. Part B, Clinical cytometry·2026
Same author

Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells.

Blood advances·2026

Human leucocyte antigen (HLA) defects in non-Hodgkin lymphomas (NHL) are linked to immune escape and disease progression. These alterations, particularly in HLA class I, are associated with relapse and transformation, suggesting a role in lymphomagenesis.

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • Optimal anti-tumor immunity relies on CD8 and CD4 T cells recognizing antigens presented by human leucocyte antigen (HLA) class I and II molecules.
  • Loss of HLA expression is a known mechanism for cancer cells to evade immune surveillance.
  • HLA-G, an immune tolerance-inducing molecule, may further facilitate tumor immune escape when expressed by cancer cells.

Purpose of the Study:

  • To investigate the frequency and patterns of HLA defects in non-Hodgkin lymphomas (NHL).
  • To assess the association between HLA alterations and clinical characteristics of NHL.
  • To explore the role of HLA-G expression in NHL immune escape.

Main Methods:

  • Prospective study of HLA expression in 614 NHL cases using flow cytometry.

Related Experiment Videos

  • Analysis of HLA-G expression in 50 NHL cases, including those with defective HLA class I.
  • Evaluation of HLA class I and HLA-DR expression levels and their correlation with NHL subtypes and outcomes.

    • Main Results:

    • Defective HLA class I expression was observed in 10.4% of NHL cases, characterized by diverse histology, frequent relapse/transformation, and higher incidence in high-grade NHL.
    • Severe HLA class I defects were noted in 50% of affected cases, predominantly in high-grade NHL.
    • A defect in HLA-DR expression, seen in 2% of cases, was always associated with a severe HLA class I defect. HLA-G was detected in three HLA class I defective cases.

    Conclusions:

    • HLA alterations, particularly defects in HLA class I and II, are frequent in NHL and associated with adverse prognostic features.
    • These HLA defects often emerge at relapse or transformation, suggesting a role in lymphomagenesis and immune escape.
    • The findings highlight the importance of HLA expression in the immune response against NHL and potential therapeutic implications.